← TrialMatch
HomeTrials

A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Da

Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate re

Condition(s)Hepatorenal Syndrome
StatusRecruiting
Study typeObservational
SummaryHepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \[1\].
Who can participateInclusion Criteria: * All patients \>18 years old that were hospitalized between April 1st 2019 and April 1st 2023 who either presented with HRS-AKI or developed a diagnosis of HRS during the hospital course. HRS-AKI will be defined based on the ICA criteria, described below: 1. Presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure 2. An increase in serum Cr of ≥0.3 mg/dL within 48 hours or ≥50% from baseline value and/or urinary output ≤0.5 mL/kg of body weight for ≥6 hours (requires use of a urinary catheter) 3. No full or partial response for ≥2 days of diuretic withdrawal and volume expansion with albumin (dosed at 1 g/kg of body weight/day) 4. Absence of shock 5. No current or recent treatment with nephrotoxic drugs 6. Absence of parenchymal renal disease 7. Su
Ages18 Years to 85 Years
SexAll
Lead sponsorMethodist Health System
LocationsDallas, Texas, United States
Start date2023-05-13
NCT IDNCT06095440
Official listinghttps://clinicaltrials.gov/study/NCT06095440

🔍 Search all trials →